NUWE

Nuwellis Inc
NASDAQHEALTHCAREMEDICAL DEVICES

Key Statistics

Market Cap
$1.15M
P/E Ratio
EPS
$-909.91
Beta
0.30
52W High
$908.25
52W Low
$2.80
50-Day MA
$21.29
200-Day MA
$65.31
Dividend Yield
Profit Margin
-217.20%
Forward P/E
PEG Ratio

About Nuwellis Inc

Nuwellis, Inc., a medical device company, focuses on the development, manufacture and marketing of medical devices used in ultrafiltration therapy. The company is headquartered in Eden Prairie, Minnesota.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$8.77M
Gross Profit (TTM)$5.74M
EBITDA$-12.45M
Operating Margin-190.10%
Return on Equity-609.00%
Return on Assets-112.90%
Revenue/Share (TTM)$259.48
Book Value$35.34
Price-to-Book0.43
Price-to-Sales (TTM)0.13
EV/Revenue0.0146
EV/EBITDA-0.34
Quarterly Earnings Growth (YoY)-99.20%
Quarterly Revenue Growth (YoY)26.20%
Shares Outstanding364,300
Float47,980
% Insiders0.15%
% Institutions1.66%

Historical Volatility

HV 10-Day
HV 20-Day
HV 30-Day
HV 60-Day
HV Rank

Latest News

Nuwellis to Showcase Aquadex Therapy at KidneyBee Summit 2026

MINNEAPOLIS, July 07, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its participation in the KidneyBee Summit 2026, taking place July 14-16, 2026, at Children's Hospital Colorado in Aurora, Colorado. As part of its participation, Nuwellis will engage with conference attendees to discuss the role of precise fluid management in pediatric patients with acute kidney injury, cardiorenal conditions, and fluid overload.

GlobeNewsWire7/7/2026Neutral
Nuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC⁴)

MINNEAPOLIS, June 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the five-year anniversary of its support of the annual conference for the Pediatric Cardiac Critical Care Consortium (PC4 ), an alliance aiming to improve the quality of care to patients with critical pediatric and congenital cardiovascular disease. Over the past five years, Nuwellis has collaborated with leading pediatric cardiac critical care institutions to support clinician education, scientific exchange, and awareness of fluid management strategies in critically ill children. Through these efforts, Nuwellis has helped foster dialogue around the growing clinical importance of fluid balance and the role of extracorporeal ultrafiltration therapies in pediatric intensive care settings.

GlobeNewsWire6/26/2026Neutral
Nuwellis Announces Pediatric Expansion in Michigan with First Aquadex SmartFlow® Installations

MINNEAPOLIS, June 25, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its expansion in Michigan with the installation of three Aquadex SmartFlow® systems at a leading pediatric healthcare provider. This represents Nuwellis' first pediatric program in the state of Michigan and further expands the Company's growing presence in pediatric critical care into a significant healthcare market.

GlobeNewsWire6/25/2026Neutral
Incoming Nuwellis CEO Mike McCormick Underscores Strategic Priorities for Continued Market Expansion in Pediatric Category and Revenue Generation in Letter to Shareholders

MINNEAPOLIS, June 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, reviews the year-to-date and outlines strategic priorities in a Letter to Shareholders from newly appointed CEO, Mike McCormick.

GlobeNewsWire6/24/2026Neutral
Nuwellis Expands Critical Care Education with Aquadex Training at University of Minnesota Critical Care Cardiology Education Summit

MINNEAPOLIS, June 18, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlighted the clinical utility of its Aquadex SmartFlow® system at the 4th annual Critical Care Cardiology Education Summit (CCCES), hosted by the University of Minnesota. As part of the conference's skills-based curriculum, conference instructors conducted focused Aquadex training sessions that provided participants with practical experience using the Company's ultrafiltration technology.

GlobeNewsWire6/18/2026Neutral
Nuwellis Appoints Mike McCormick as Chief Executive Officer

Transition to become effective June 30, 2026; current CEO John Erb to continue as Chairman of the Board Transition to become effective June 30, 2026; current CEO John Erb to continue as Chairman of the Board

GlobeNewsWire6/16/2026Neutral
Nuwellis Announces Closing of $6.0 Million Registered Public Offering

MINNEAPOLIS , June 08, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces the closing of a public offering of 1,903,338 shares of its common stock ("Common Stock"), pre-funded warrants to purchase 18,096,662 shares of Common Stock, in each case with accompanying Series C Warrants to purchase up to 60,000,000 shares of Common Stock and Series D Warrants to purchase up to 20,000,000 shares of Common Stock with gross proceeds of approximately $6.0 million.

GlobeNewsWire6/9/2026Neutral
Nuwellis Announces Pricing of $6 Million Public Offering

MINNEAPOLIS, June 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces the pricing of a public offering of 20,000,000 shares of its common stock ("Common Stock") (or pre-funded warrants in lieu thereof) with accompanying warrants to purchase common stock for gross proceeds of approximately $6 million (the “Offering”).

GlobeNewsWire6/5/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026